Navigation Links
Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
Date:9/27/2007

SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company's common shares are now eligible to be included in the NASDAQ Global Market and will begin trading there under the same symbol "PARD" effective Monday, October 1, 2007.

"Qualifying for listing on the NASDAQ Global Market represents an important milestone for Poniard and provides us with greater visibility in the global financial markets and broadens our exposure to new investors," said Caroline Loewy, chief financial officer of Poniard. "This is an important step in our continued growth and demonstrates our ability to meet the higher standards required by the NASDAQ Global Market."

NASDAQ-listed companies are classified under three listing tiers -- NASDAQ Global Select Market, NASDAQ Global Market and NASDAQ Capital Market. Poniard has been listed on the NASDAQ Capital Market. All three market tiers maintain rigorous listing and corporate governance standards. For additional information about the NASDAQ Global Market, please visit http://www.nasdaq.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
Breaking Biology News(10 mins):